CSJ148
Total Payments
$101,924
Transactions
3
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1,743 | 1 | 1 |
| 2017 | $100,181 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $101,924 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CSJ148 COMPARED TO PLACEBO TO PREVENT HUMAN CYTOMEGALOVIRUS HCMV REPLICATION IN STEM CELL TRANSPLANT PATIENTS | Novartis Pharmaceuticals Corporation | $100,181 | 0 |
| A MULTICENTER RANDOMIZED PATIENT INVESTIGATOR AND SPONSOR BLINDED PLACEBO CONTROLLED PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CSJ148 IN PREGNANT WOMEN WITH PRIMARY HCMV INFECTION | NOVARTIS PHARMACEUTICALS CORPORATION | $1,743 | 1 |
Top Doctors Receiving Payments for CSJ148
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Gainesville, FL | $100,181 | 2 |
| , M.D | Obstetrics & Gynecology | Pittsburgh, PA | $1,743 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $101,924
- Total Doctors 1
- Transactions 3
About CSJ148
CSJ148 is a drug associated with $101,924 in payments to 1 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $1,743 was paid across 1 transactions to 1 doctors.
The most common payment nature for CSJ148 is "Unspecified" ($101,924, 100.0% of total).
CSJ148 is associated with 2 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CSJ148 COMPARED TO PLACEBO TO PREVENT HUMAN CYTOMEGALOVIRUS HCMV REPLICATION IN STEM CELL TRANSPLANT PATIENTS" ($100,181).